Literature DB >> 843810

Adjuvant therapy of lung cancer.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843810      PMCID: PMC1605201     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  8 in total

1.  Complete and apparently specif local tumor regression using syngeneic or xenogeneic "tumor-immune" RNA extracts.

Authors:  S I Schlager; R E Paque; S Dray
Journal:  Cancer Res       Date:  1975-08       Impact factor: 12.701

Review 2.  Tumor antigens and tumor-host relationships.

Authors:  R W Baldwin; M R Price
Journal:  Annu Rev Med       Date:  1976       Impact factor: 13.739

3.  Delayed-hypersensitivity reactions to soluble membrane antigens of human malignant lung cells.

Authors:  A C Hollinshead; T H Stewart; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

4.  Lymphocyte responses of lung cancer patients to tumor-associated antigen measured by leucine incorporation.

Authors:  J A Roth; E C Holmes; A W Boddie; D L Morton
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

5.  A plasma membrane antigen highly associated with oat-cell carcinoma of the lung and undetectable in normal adult tissue.

Authors:  C E Bell; S Seetharam
Journal:  Int J Cancer       Date:  1976-11-15       Impact factor: 7.396

6.  Extraction and preliminary characterization of a human bronchogenic carcinoma antigen.

Authors:  M J Frost; G T Rogers; K D Bagshawe
Journal:  Br J Cancer       Date:  1975-04       Impact factor: 7.640

7.  Protection of mice against syngeneic lymphomata: I. Use of antibodies.

Authors:  D A Davies; A J Manstone; S Buckham
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

8.  Protection of mice against syngeneic lymphomata: II. Collaboration between drugs and antibodies.

Authors:  D A Davies; S Buckham; A J Manstone
Journal:  Br J Cancer       Date:  1974-10       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.